Cargando…

Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer

BACKGROUND: Malignant bowel obstruction (MBO) is a common cause of morbidity and mortality in women diagnosed with ovarian cancer. Earlier detection of MBO may improve patient outcomes. There are currently no screening tools to assist detection. AIM: We report a screening questionnaire that can be u...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgan, Robert D, Stamatopoulou, Sofia, Mescallado, Nerissa, Saunders, Geoff, Welch, Richard, Mitchell, Claire, Hasan, Jurjees, Clamp, Andrew R, Jayson, Gordon C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435240/
https://www.ncbi.nlm.nih.gov/pubmed/30962962
http://dx.doi.org/10.1136/esmoopen-2018-000463
_version_ 1783406621236396032
author Morgan, Robert D
Stamatopoulou, Sofia
Mescallado, Nerissa
Saunders, Geoff
Welch, Richard
Mitchell, Claire
Hasan, Jurjees
Clamp, Andrew R
Jayson, Gordon C
author_facet Morgan, Robert D
Stamatopoulou, Sofia
Mescallado, Nerissa
Saunders, Geoff
Welch, Richard
Mitchell, Claire
Hasan, Jurjees
Clamp, Andrew R
Jayson, Gordon C
author_sort Morgan, Robert D
collection PubMed
description BACKGROUND: Malignant bowel obstruction (MBO) is a common cause of morbidity and mortality in women diagnosed with ovarian cancer. Earlier detection of MBO may improve patient outcomes. There are currently no screening tools to assist detection. AIM: We report a screening questionnaire that can be used to detect MBO, and how the severity score for key clinical symptoms correlate with radiological evidence of MBO from ovarian cancer. DESIGN: A case–control study in which patients with relapsed, metastatic ovarian cancer were asked to answer 10 questions related to key clinical symptoms associated with intestinal obstruction. The study group included women with CT-confirmed MBO, whereas the control group had no evidence of MBO. Patients scored each question according to severity from 1 (least severe) to 5 (most severe). SETTING/PARTICIPANTS: Between 1 June and 31 December 2016, 37 women completed the screening questionnaire. RESULTS: Patients in the study group (n=17) reported significantly higher (ie, more severe) scores for abdominal pain, nausea, vomiting and constipation. In contrast, differences in severity scores between groups did not differ significantly in response to questions regarding abdominal swelling, borborygmi, diarrhoea or loss of appetite. All patients in the study group more frequently stated that their symptoms had deteriorated within the 2 months prior to completing the questionnaire. CONCLUSION: Here we report the key clinical symptoms associated with radiologically-confirmed MBO in relapsed, metastatic ovarian cancer. We recommend healthcare practitioners focus on these specific symptoms during patient consultations in order to improve risk stratification of MBO.
format Online
Article
Text
id pubmed-6435240
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-64352402019-04-08 Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer Morgan, Robert D Stamatopoulou, Sofia Mescallado, Nerissa Saunders, Geoff Welch, Richard Mitchell, Claire Hasan, Jurjees Clamp, Andrew R Jayson, Gordon C ESMO Open Original Research BACKGROUND: Malignant bowel obstruction (MBO) is a common cause of morbidity and mortality in women diagnosed with ovarian cancer. Earlier detection of MBO may improve patient outcomes. There are currently no screening tools to assist detection. AIM: We report a screening questionnaire that can be used to detect MBO, and how the severity score for key clinical symptoms correlate with radiological evidence of MBO from ovarian cancer. DESIGN: A case–control study in which patients with relapsed, metastatic ovarian cancer were asked to answer 10 questions related to key clinical symptoms associated with intestinal obstruction. The study group included women with CT-confirmed MBO, whereas the control group had no evidence of MBO. Patients scored each question according to severity from 1 (least severe) to 5 (most severe). SETTING/PARTICIPANTS: Between 1 June and 31 December 2016, 37 women completed the screening questionnaire. RESULTS: Patients in the study group (n=17) reported significantly higher (ie, more severe) scores for abdominal pain, nausea, vomiting and constipation. In contrast, differences in severity scores between groups did not differ significantly in response to questions regarding abdominal swelling, borborygmi, diarrhoea or loss of appetite. All patients in the study group more frequently stated that their symptoms had deteriorated within the 2 months prior to completing the questionnaire. CONCLUSION: Here we report the key clinical symptoms associated with radiologically-confirmed MBO in relapsed, metastatic ovarian cancer. We recommend healthcare practitioners focus on these specific symptoms during patient consultations in order to improve risk stratification of MBO. BMJ Publishing Group 2019-03-21 /pmc/articles/PMC6435240/ /pubmed/30962962 http://dx.doi.org/10.1136/esmoopen-2018-000463 Text en © Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research
Morgan, Robert D
Stamatopoulou, Sofia
Mescallado, Nerissa
Saunders, Geoff
Welch, Richard
Mitchell, Claire
Hasan, Jurjees
Clamp, Andrew R
Jayson, Gordon C
Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer
title Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer
title_full Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer
title_fullStr Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer
title_full_unstemmed Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer
title_short Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer
title_sort screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435240/
https://www.ncbi.nlm.nih.gov/pubmed/30962962
http://dx.doi.org/10.1136/esmoopen-2018-000463
work_keys_str_mv AT morganrobertd screeningtoolformalignantbowelobstructioninrelapsedmetastaticovariancancer
AT stamatopoulousofia screeningtoolformalignantbowelobstructioninrelapsedmetastaticovariancancer
AT mescalladonerissa screeningtoolformalignantbowelobstructioninrelapsedmetastaticovariancancer
AT saundersgeoff screeningtoolformalignantbowelobstructioninrelapsedmetastaticovariancancer
AT welchrichard screeningtoolformalignantbowelobstructioninrelapsedmetastaticovariancancer
AT mitchellclaire screeningtoolformalignantbowelobstructioninrelapsedmetastaticovariancancer
AT hasanjurjees screeningtoolformalignantbowelobstructioninrelapsedmetastaticovariancancer
AT clampandrewr screeningtoolformalignantbowelobstructioninrelapsedmetastaticovariancancer
AT jaysongordonc screeningtoolformalignantbowelobstructioninrelapsedmetastaticovariancancer